NASDAQ OMX

Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm

Dela

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions.

"We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertise. Each of these solutions are designed to be quickly deployed and support the end-to-end processes of our customers, from the required content to cloud-based hosting."

According to the report: "The Nasdaq BWise platform has a strong regulatory change management offering for heavily regulated environments, and it's gaining traction with buyers in the midmarket and in information security organizations. Customers continue to extend their implementations with additional use cases and grow the application's footprint in the enterprise."

"We believe obtaining the maximum score for the evaluation criteria 'Financial Resources to Support Strategy', is a reflection of the dedicated investment that Nasdaq has made-and is continuing to make-into the BWise GRC platform," said Jonathan Deeks, Global Head of GRC, Nasdaq. "This ensures the platform and solutions remain at the forefront of the industry for years to come."

To download a copy of the report, visit the Nasdaq BWise website.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com   

About BWise

BWise is an integral part of Nasdaq's wider GRC offering designed to help organizations, public and private, improve their operational management. Thousands of users in virtually every industry rely on the BWise® risk management solutions to track, measure and manage their reputational and financial risks and support their GRC processes on a daily basis.

For more information, go to www.bwise.com 

For Media Inquiries:

Nasdaq
Ryan Wells
ryan.wells@nasdaq.com
Direct: +44 (0) 20 3753 2231
Mobile:  +44 (0) 7809 596 390




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hoylu AB: UNITED STATES ARMY SELECTS HOYLU FOR DIGITAL COLLABORATION SOLUTIONS26.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 26, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Army has selected Hoylu Software and the large format HoyluWall system as a digital workspace tool for workspace collaboration, process planning and ideation. Hoylu software will be used to modify, save, print and communicate between teams at remote locations and allow for collaborative analysis. The order will be delivered in Q3 2018 and represents a deal value of SEK 528,000 in product and software revenue and presents ongoing opportunities to expand within the government sector. This system will be installed at the Picatinny Arsenal in New Jersey, the US Army's primary R&D arm for armament and munitions systems. Picatinny Arsenal is the Joint Center of Excellence for Guns and Ammunition, providing products and services to all branches of the U.S. military. Picatinny Arsenal has partnerships with a variety of universities and industry partners, involving them i

Hoylu AB: USA:s armé väljer Hoylu för digitala samarbetslösningar26.9.2018 08:30Pressmeddelande

Malmö, Sverige, 26:e september 2018 - Hoylu, ett ledande företag inom digitala samarbetslösningar tillkännagav idag att USA:s armé har valt Hoylus mjukvara och storformats Hoylu Wall-system som verktyg för digitalt samarbete, delade arbetsytor, processplanering och idégenerering. Hoylus mjukvara kommer användas till att modifiera, spara, skriva ut och stödja samarbete mellan team på olika platser samt möjliggöra kollaborativ analys. Ordern kommer levereras under tredje kvartalet 2018 och har ett sammanlagt värde på SEK 528 000 för hård- och mjukvara. Ordern visar på ökande möjligheter att växa inom statlig och offentlig verksamhet. Systemet kommer installeras på Picatinny Arsenal i New Jersey, USA:s armés primära R&D-enhet för vapen- och ammunitionssystem. Picatinny Arsenal är ett s.k. "Joint Center of Excellence" för vapen och ammunition och de tillhandahåller produkter och tjänster åt alla grenar av USA:s armé. Picatinny Arsenal har också samarbeten med en mängd olika universitet och

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum